ChromaDex Corp. logo

ChromaDex Corp. (CDXC)

Market Closed
18 Mar, 20:00
NASDAQ (CM) NASDAQ (CM)
$
7. 87
-0.07
-0.88%
$
611.9M Market Cap
- P/E Ratio
0% Div Yield
541,672 Volume
-0.01 Eps
$ 7.94
Previous Close
Day Range
7.75 7.92
Year Range
2.31 9.18
Want to track CDXC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 9 days
Are Medical Stocks Lagging ChromaDex (CDXC) This Year?

Are Medical Stocks Lagging ChromaDex (CDXC) This Year?

Here is how ChromaDex (CDXC) and Bioventus (BVS) have performed compared to their sector so far this year.

Zacks | 9 months ago
Is ChromaDex (CDXC) Stock Outpacing Its Medical Peers This Year?

Is ChromaDex (CDXC) Stock Outpacing Its Medical Peers This Year?

Here is how ChromaDex (CDXC) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

Zacks | 10 months ago
ChromaDex (CDXC) Reports Break-Even Earnings for Q2

ChromaDex (CDXC) Reports Break-Even Earnings for Q2

ChromaDex (CDXC) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.03 per share a year ago.

Zacks | 11 months ago
ChromaDex: Looking To Take The Big Step Into Pharma

ChromaDex: Looking To Take The Big Step Into Pharma

ChromaDex Corporation is a leader in NAD+ development for healthy aging with Tru Niagen, showing strong growth and attractive valuation. ChromaDex is making a move into the pharma industry with NRC candidate for AT, receiving FDA designations and preparing for clinical trials. Potential risks include cash burn, competition, and IP challenges, but the company's dual focus on pharma and nutraceuticals offers significant upside.

Seekingalpha | 1 year ago
ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag

ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag

ChromaDex (CDXC) rises 12% as the FDA grants the Orphan Drug Designation and the Rare Pediatric Disease Designation to its investigational candidate, NRC, to treat ataxia telangiectasia.

Zacks | 1 year ago